However, although this finding needs to be confirmed in largest cohort of patients, DNMT3A mutations could be a predictive factor for response to idarubicin and, thus could have a direct influence in the way AML patients should be managed. This evidence concerns the gene DNMT3A and acute myeloid leukemia.